Effect of Active Folate Compared With Folic Acid on Homocysteine Levels in Postmenopausal Women With Metabolic Syndrome: A Triple-Blind Randomized Clinical Trial
In a triple-blind randomized clinical trial involving postmenopausal women with metabolic syndrome, both folic acid and 5-methyltetrahydrofolate significantly reduced plasma homocysteine levels over three months, but 5-methyltetrahydrofolate offered no statistically significant advantage over folic acid in homocysteine reduction or short-term cardiometabolic outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, doctors have known that a specific chemical in the blood, called homocysteine, acts as a warning sign for heart trouble. When levels of this substance climb too high, the lining of the blood vessels can become damaged, making it easier for blockages to form that lead to heart attacks or strokes. This risk is particularly sharp for women after menopause. As estrogen levels drop, homocysteine levels often rise, and when combined with other common issues like high blood pressure or excess weight, the danger to the heart grows significantly. The body normally keeps homocysteine in check using a specific form of vitamin B9, known as folate, but the way the body processes this vitamin can vary from person to person. Some people struggle to convert the common, synthetic version of folate found in supplements into the active form their bodies can actually use. This has led to a question in the medical community: is the standard, inexpensive folic acid supplement enough, or should doctors switch to a pricier, "active" version of the vitamin that requires no conversion?
To answer this, a team of researchers in Tehran, Iran, conducted a carefully controlled experiment involving fifty postmenopausal women who already had metabolic syndrome, a cluster of conditions that raises heart disease risk. The study was designed to be completely blind, meaning neither the women, the doctors treating them, nor the scientists analyzing the data knew which supplement each woman was taking. The participants were split into two equal groups. One group took a daily pill containing one milligram of standard folic acid, while the other group took a daily pill containing 0.6 milligrams of the active form, known as 5-methyltetrahydrofolate. The women took these supplements for three months, and the researchers measured their blood levels at the start and at the end of the trial to see how their bodies responded.
The results showed that both groups made significant progress in lowering their homocysteine levels. After three months, the women in the standard folic acid group saw their levels drop, and the women in the active folate group saw a similar drop. When the researchers compared the two groups directly, they found no meaningful difference in how much the homocysteine levels fell. The active form did not lower the dangerous chemical any better than the standard version. However, there was a clear difference in how the vitamins behaved inside the body. The women taking the active folate saw a much larger increase in their overall folate levels in the blood compared to those taking the standard folic acid. It is as if the active vitamin was more efficient at raising the total amount of the nutrient circulating in the blood, but this extra boost did not translate into a greater reduction of the harmful homocysteine.
Beyond the vitamin levels, the researchers looked at a wide range of other health markers to see if one supplement offered broader benefits. They checked the women's weight, waist size, blood pressure, blood sugar, and cholesterol levels. They also examined liver function. Over the three-month period, neither group showed significant improvements in these areas. The supplements did not lower blood pressure, improve cholesterol, or change body measurements in a way that could be distinguished from normal daily fluctuations. The study also confirmed that both supplements were safe, with no serious side effects reported by the participants.
The findings suggest that for postmenopausal women with metabolic syndrome, the standard, low-cost folic acid is just as effective as the more expensive active form at lowering homocysteine levels over a short period. While the active version does raise blood folate levels more dramatically, this extra boost does not appear to provide a stronger shield against heart risk in the form of lower homocysteine or better metabolic health. The researchers concluded that for the goal of reducing homocysteine in this specific group of women, there is no clear advantage to choosing the pricier active supplement over the traditional one. The choice between the two does not need to be based on the expectation that one will work better than the other for this specific purpose.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.